source
- Pain drug research gains momentum a year after Vertex launch as new startups revive sodium channel targetsA year after Vertex introduced its breakthrough pain medication, the field of pain drug development is at a pivotal crossroads. Analysts note that renewed scientific focus and investor interest are…
- Eli Lilly suggests low-dose Zepbound and Foundayo could safely maintain weight loss at lower costNew trial data indicate that lowering the dose of Eli Lilly's obesity injection Zepbound may still provide effective weight‑loss maintenance while improving safety. The study also highlights Found…